메뉴 건너뛰기




Volumn 68, Issue 1, 2016, Pages 29-36

Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study

(13)  Ogawa, Hisao a,b   Isshiki, Takaaki c   Kimura, Takeshi d   Yokoi, Hiroyoshi e,f   Nanto, Shinsuke g   Takayama, Morimasa h   Kitagawa, Kazuo i   Nishikawa, Masakatsu j   Miyazaki, Shunichi k   Ikeda, Yasuo l   Nakamura, Masato m   Tanaka, Yuko n   Saito, Shigeru o  


Author keywords

Clopidogrel; CYP2C19; Major adverse cardiovascular events; Platelet aggregation; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT; CYTOCHROME P450 2C19; TICLOPIDINE;

EID: 84951803750     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.07.019     Document Type: Article
Times cited : (44)

References (32)
  • 1
    • 84866904806 scopus 로고    scopus 로고
    • Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009)
    • [in Japanese]
    • Murasaki K. Guidelines for management of anticoagulant and antiplatelet therapy in cardiovascular disease (JCS 2009). Nihon Rinsho 2011, 69(Suppl. 9):567-571. [in Japanese].
    • (2011) Nihon Rinsho , vol.69 , pp. 567-571
    • Murasaki, K.1
  • 4
    • 33749339075 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    • Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
    • (2006) Blood , vol.108 , pp. 2244-2247
    • Hulot, J.S.1    Bura, A.2    Villard, E.3    Azizi, M.4    Remones, V.5    Goyenvalle, C.6    Aiach, M.7    Lechat, P.8    Gaussem, P.9
  • 8
    • 84876923072 scopus 로고    scopus 로고
    • Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention
    • Tang X.F., Zhang J.H., Wang J., Han Y.L., Xu B., Qiao S.B., Wu Y.J., Chen J., Wu Y., Chen J.L., Gao R.L., Yang Y.J., Yuan J.Q. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl) 2013, 126:1069-1075.
    • (2013) Chin Med J (Engl) , vol.126 , pp. 1069-1075
    • Tang, X.F.1    Zhang, J.H.2    Wang, J.3    Han, Y.L.4    Xu, B.5    Qiao, S.B.6    Wu, Y.J.7    Chen, J.8    Wu, Y.9    Chen, J.L.10    Gao, R.L.11    Yang, Y.J.12    Yuan, J.Q.13
  • 11
    • 84892406763 scopus 로고    scopus 로고
    • Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention
    • Desai N.R., Canestaro W.J., Kyrychenko P., Chaplin D., Martell L.A., Brennan T., Matlin O.S., Choudhry N.K. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes 2013, 6:694-699.
    • (2013) Circ Cardiovasc Qual Outcomes , vol.6 , pp. 694-699
    • Desai, N.R.1    Canestaro, W.J.2    Kyrychenko, P.3    Chaplin, D.4    Martell, L.A.5    Brennan, T.6    Matlin, O.S.7    Choudhry, N.K.8
  • 12
    • 84873033234 scopus 로고    scopus 로고
    • Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis
    • Lala A., Berger J.S., Sharma G., Hochman J.S., Scott Braithwaite R., Ladapo J.A. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. J Thromb Haemost 2013, 11:81-91.
    • (2013) J Thromb Haemost , vol.11 , pp. 81-91
    • Lala, A.1    Berger, J.S.2    Sharma, G.3    Hochman, J.S.4    Scott Braithwaite, R.5    Ladapo, J.A.6
  • 13
    • 84889055569 scopus 로고    scopus 로고
    • Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia
    • Sorich M.J., Horowitz J.D., Sorich W., Wiese M.D., Pekarsky B., Karnon J.D. Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. Pharmacogenomics 2013, 14:2013-2021.
    • (2013) Pharmacogenomics , vol.14 , pp. 2013-2021
    • Sorich, M.J.1    Horowitz, J.D.2    Sorich, W.3    Wiese, M.D.4    Pekarsky, B.5    Karnon, J.D.6
  • 18
    • 18044398749 scopus 로고    scopus 로고
    • Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
    • Niitsu Y., Jakubowski J.A., Sugidachi A., Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005, 31:184-194.
    • (2005) Semin Thromb Hemost , vol.31 , pp. 184-194
    • Niitsu, Y.1    Jakubowski, J.A.2    Sugidachi, A.3    Asai, F.4
  • 20
    • 84903208627 scopus 로고    scopus 로고
    • Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS Study
    • Saito S., Isshiki T., Kimura T., Ogawa H., Yokoi H., Nanto S., Takayama M., Kitagawa K., Nishikawa M., Miyazaki S., Nakamura M. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS Study. Circ J 2014, 78:1684-1692.
    • (2014) Circ J , vol.78 , pp. 1684-1692
    • Saito, S.1    Isshiki, T.2    Kimura, T.3    Ogawa, H.4    Yokoi, H.5    Nanto, S.6    Takayama, M.7    Kitagawa, K.8    Nishikawa, M.9    Miyazaki, S.10    Nakamura, M.11
  • 21
    • 0022220338 scopus 로고
    • Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians
    • Jurima M., Inaba T., Kadar D., Kalow W. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985, 19:483-487.
    • (1985) Br J Clin Pharmacol , vol.19 , pp. 483-487
    • Jurima, M.1    Inaba, T.2    Kadar, D.3    Kalow, W.4
  • 22
    • 0022178173 scopus 로고
    • Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
    • Nakamura K., Goto F., Ray W.A., McAllister C.B., Jacqz E., Wilkinson G.R., Branch R.A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985, 38:402-408.
    • (1985) Clin Pharmacol Ther , vol.38 , pp. 402-408
    • Nakamura, K.1    Goto, F.2    Ray, W.A.3    McAllister, C.B.4    Jacqz, E.5    Wilkinson, G.R.6    Branch, R.A.7
  • 24
    • 84929411451 scopus 로고    scopus 로고
    • Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina
    • Arima Y., Hokimoto S., Akasaka T., Mizobe K., Kaikita K., Oniki K., Nakagawa K., Ogawa H. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina. J Cardiol 2015, 65:494-500.
    • (2015) J Cardiol , vol.65 , pp. 494-500
    • Arima, Y.1    Hokimoto, S.2    Akasaka, T.3    Mizobe, K.4    Kaikita, K.5    Oniki, K.6    Nakagawa, K.7    Ogawa, H.8
  • 26
    • 66349103930 scopus 로고    scopus 로고
    • Bedside evaluation of thienopyridine antiplatelet therapy
    • Price M.J. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009, 119:2625-2632.
    • (2009) Circulation , vol.119 , pp. 2625-2632
    • Price, M.J.1
  • 27
    • 60749108941 scopus 로고    scopus 로고
    • MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets
    • Siddiqui O., Hung M.J., O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009, 19:227-246.
    • (2009) J Biopharm Stat , vol.19 , pp. 227-246
    • Siddiqui, O.1    Hung, M.J.2    O'Neill, R.3
  • 31
    • 67649158245 scopus 로고    scopus 로고
    • Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction
    • Morrow D.A., Wiviott S.D., White H.D., Nicolau J.C., Bramucci E., Murphy S.A., Bonaca M.P., Ruff C.T., Scirica B.M., McCabe C.H., Antman E.M., Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009, 119:2758-2764.
    • (2009) Circulation , vol.119 , pp. 2758-2764
    • Morrow, D.A.1    Wiviott, S.D.2    White, H.D.3    Nicolau, J.C.4    Bramucci, E.5    Murphy, S.A.6    Bonaca, M.P.7    Ruff, C.T.8    Scirica, B.M.9    McCabe, C.H.10    Antman, E.M.11    Braunwald, E.12
  • 32
    • 84973545171 scopus 로고    scopus 로고
    • Efficacy and safety of prasugrel in Japanese cardiovascular disease patients undergoing PCI
    • [in Japanese]
    • Nishikawa Y. Efficacy and safety of prasugrel in Japanese cardiovascular disease patients undergoing PCI. Prog Med 2014, 34:1467-1473. [in Japanese].
    • (2014) Prog Med , vol.34 , pp. 1467-1473
    • Nishikawa, Y.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.